BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

...the PDE4 inhibitor in 2H21. Prothena gains on plans for Phase III AL amyloidosis studyShares of Prothena Corp. plc...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

...Scripps Research Institute Orphan Technologies Ltd. Genmab A/S Johnson & Johnson Prothena Corp. plc Valneva...
BioCentury | Apr 23, 2020
Product Development

Roche reveals trial failures

...showed signs of efficacy and that it will continue to evaluate next steps. Roche’s partner Prothena Corp. plc...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...created position. He was SVP and general counsel at Insulet Corp. (NASDAQ:PODD). Neurological disorder play Prothena Corp. plc...
...and Robin Sawka, BioCentury Staff Ultragenyx Pharmaceutical Inc. Axsome Therapeutics Inc. ElevateBio LLC Satsuma Pharmaceuticals Inc. WindMIL Therapeutics Inc. Anika Therapeutics Inc. Prothena Corp. plc MacroGenics...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...Inc. (NASDAQ:PTCT). Its Phase II Parkinson’s disease and Alzheimer’s disease programs came through partnerships with Prothena Corp. plc...
BioCentury | Sep 17, 2019
Company News

Management tracks: Gottlieb joins Aetion board; plus Alexion, Encoded, PhRMA, Rgenix, Lyra, twoXAR and Innoplexus

...NYSE:NVS; SIX:NOVN). The company also hired David McNinch as CBO. He was formerly CCO at Prothena Corp. plc...
BioCentury | Aug 28, 2019
Company News

Aug. 28 Company Quick Takes: Amgen to appeal Repatha ruling and EcoR1 buys Woodford’s stake in Prothena; plus DarwinHealth-Celgene, CRISPR IP, Trevena and Shink

...Repatha Claims” ). EcoR1 acquires Woodford’s stake in Prothena EcoR1 Capital acquired the stake in Prothena Corp. plc...
...a series of troubles that have followed a long period of its flagship fund’s underperformance. Prothena...
...of a 23.6% stake in an SEC filing, but the seller’s identity was not revealed. Prothena...
BioCentury | Aug 27, 2019
Financial News

Aug. 27 Financial Quick Takes: Prothena gains on EcoR1 investment; plus Pharmaron, Exagen

...EcoR1 takes stake in Prothena Prothena Corp. plc (NASDAQ:PRTA) jumped $1.87 (27%) to $8.93 Tuesday after it disclosed...
...Fund, Tullis-Dickerson Capital Focus, Hunt Holdings and H.I.G. Elizabeth S. Eaton, Staff Writer Exagen Diagnostics Inc. Pharmaron Holding Ltd. Prothena Corp. plc EcoR1...
BioCentury | Apr 26, 2019
Clinical News

Prothena sees potential path forward for amyloidosis candidate

...a potential survival benefit in a subgroup of patients at highest risk for early mortality. Prothena Corp. plc...
...vs. placebo among 77 AL amyloidosis patients categorized as Mayo Stage IV. In April 2018, Prothena...
...trial for the indication, and an IDMC recommended discontinuing VITAL following a futility analysis (see "Prothena...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...of Europe, a newly created position. He was VP, head of European commercial operations at Prothena Corp. plc...
Items per page:
1 - 10 of 101
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

...the PDE4 inhibitor in 2H21. Prothena gains on plans for Phase III AL amyloidosis studyShares of Prothena Corp. plc...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

...Scripps Research Institute Orphan Technologies Ltd. Genmab A/S Johnson & Johnson Prothena Corp. plc Valneva...
BioCentury | Apr 23, 2020
Product Development

Roche reveals trial failures

...showed signs of efficacy and that it will continue to evaluate next steps. Roche’s partner Prothena Corp. plc...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...created position. He was SVP and general counsel at Insulet Corp. (NASDAQ:PODD). Neurological disorder play Prothena Corp. plc...
...and Robin Sawka, BioCentury Staff Ultragenyx Pharmaceutical Inc. Axsome Therapeutics Inc. ElevateBio LLC Satsuma Pharmaceuticals Inc. WindMIL Therapeutics Inc. Anika Therapeutics Inc. Prothena Corp. plc MacroGenics...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...Inc. (NASDAQ:PTCT). Its Phase II Parkinson’s disease and Alzheimer’s disease programs came through partnerships with Prothena Corp. plc...
BioCentury | Sep 17, 2019
Company News

Management tracks: Gottlieb joins Aetion board; plus Alexion, Encoded, PhRMA, Rgenix, Lyra, twoXAR and Innoplexus

...NYSE:NVS; SIX:NOVN). The company also hired David McNinch as CBO. He was formerly CCO at Prothena Corp. plc...
BioCentury | Aug 28, 2019
Company News

Aug. 28 Company Quick Takes: Amgen to appeal Repatha ruling and EcoR1 buys Woodford’s stake in Prothena; plus DarwinHealth-Celgene, CRISPR IP, Trevena and Shink

...Repatha Claims” ). EcoR1 acquires Woodford’s stake in Prothena EcoR1 Capital acquired the stake in Prothena Corp. plc...
...a series of troubles that have followed a long period of its flagship fund’s underperformance. Prothena...
...of a 23.6% stake in an SEC filing, but the seller’s identity was not revealed. Prothena...
BioCentury | Aug 27, 2019
Financial News

Aug. 27 Financial Quick Takes: Prothena gains on EcoR1 investment; plus Pharmaron, Exagen

...EcoR1 takes stake in Prothena Prothena Corp. plc (NASDAQ:PRTA) jumped $1.87 (27%) to $8.93 Tuesday after it disclosed...
...Fund, Tullis-Dickerson Capital Focus, Hunt Holdings and H.I.G. Elizabeth S. Eaton, Staff Writer Exagen Diagnostics Inc. Pharmaron Holding Ltd. Prothena Corp. plc EcoR1...
BioCentury | Apr 26, 2019
Clinical News

Prothena sees potential path forward for amyloidosis candidate

...a potential survival benefit in a subgroup of patients at highest risk for early mortality. Prothena Corp. plc...
...vs. placebo among 77 AL amyloidosis patients categorized as Mayo Stage IV. In April 2018, Prothena...
...trial for the indication, and an IDMC recommended discontinuing VITAL following a futility analysis (see "Prothena...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...of Europe, a newly created position. He was VP, head of European commercial operations at Prothena Corp. plc...
Items per page:
1 - 10 of 101